TRKing down drug resistance in NTRK fusion‐positive cancers †
The Journal of Pathology · 2024
DOI: 10.1002/path.6341 ↗At a glance
Kommentar in The Journal of Pathology, 2024. Written by Abigail G Parrish and 1 co-authors. Institution: Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA. Major MEDLINE topics: Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Cited 4 times so far (Crossref); 11 references.
Abstract (original language)
In a recent issue of The Journal of Pathology , Chen and colleagues established novel patient‐derived ex vivo models of NTRK fusion‐positive soft tissue sarcoma to characterize resistance mechanisms against targeted therapy with tyrosine kinase inhibitors. Prolonged exposure to escalating concentrations of the tyrosine kinase inhibitor, entrectinib, ultimately led to the occurrence of resistant clones that harbored an inactivating mutation in the NF2 gene, not previously described in this context, accompanied by increased PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling. Finally, an inhibitor screen identified, among others, MEK and mTOR inhibitors as potential combination agents. © 2024 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
ORCID profiles: Abigail G Parrish, Frank Szulzewsky
Cite
APA
Parrish, A. G., & Szulzewsky, F. (2024). TRKing down drug resistance in NTRK fusion‐positive cancers †. The Journal of Pathology. https://doi.org/10.1002/path.6341
Vancouver
Parrish AG, Szulzewsky F. TRKing down drug resistance in NTRK fusion‐positive cancers †. The Journal of Pathology. 2024. doi:10.1002/path.6341
BibTeX
@article{Parrish2024,
author = {Parrish, Abigail G and Szulzewsky, Frank},
title = {TRKing down drug resistance in NTRK fusion‐positive cancers †},
journal = {The Journal of Pathology},
year = {2024},
doi = {10.1002/path.6341}
}
EUVIMED